D. Mavroudis - Concepedia

Author

D. Mavroudis

Also Known As

D Mavroudis, D. Mavroudis, Dimitrios A. Mavroudis, H. Lindman, Hamann, U., Janni, W., Plaseska-Karanfilska, D., Truong, T.

129

Publications

3.4K

Citations

H-Index

Concepts

All Affiliations

University Hospital of Heraklion University of Crete Hellenic Oncology Research Group KAT General Hospital of Attica Sotiria General Hospital

About

D. Mavroudis is an author at University Hospital of Heraklion specializing in oncology, medicine, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	22	1.2K
2	Health Sciences	5	5	102
3	Public Health	1	1	94
4	Cell Biology	1	1	59
5	Clinical Nutrition	1	1	94

D. Mavroudis

Publications

3.1K

Citations

H-Index

Page 1

	Year	Citations
FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG) John Souglakos, N. Androulakis, K. Syrigos, British Journal of Cancer	2006	399
Molecular Detection of Cytokeratin-19–Positive Cells in the Peripheral Blood of Patients With Operable Breast Cancer: Evaluation of Their Prognostic Significance Aliki Stathopoulou, Ioannis G. Vlachonikolis, D. Mavroudis, Journal of Clinical Oncology	2002	340
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC Aristea Kalikaki, Anastasios Koutsopoulos, Maria Trypaki, British Journal of Cancer	2008	207
Six versus 12 months of adjuvant trastuzumab in combination with dose-dense chemotherapy for women with HER2-positive breast cancer: a multicenter randomized study by the Hellenic Oncology Research Group (HORG) D. Mavroudis, Emmanouil Saloustros, N. Malamos, Annals of Oncology Breast OncologyOncologyDose-dense ChemotherapyBreast CancerAdjuvant Trastuzumab	2015	162
Trastuzumab decreases the incidence of clinical relapses in patients with early breast cancer presenting chemotherapy-resistant CK-19mRNA-positive circulating tumor cells: results of a randomized phase II study Vasilis Georgoulias, V. Bozionelou, Sofia Agelaki, Annals of Oncology Tumor BiologyBreast OncologyEarly Breast CancerClinical RelapsesMedicine	2012	147
Triplet Combination With Irinotecan Plus Oxaliplatin Plus Continuous-Infusion Fluorouracil and Leucovorin as First-Line Treatment in Metastatic Colorectal Cancer: A Multicenter Phase II Trial John Souglakos, D. Mavroudis, Stylianos Kakolyris, Journal of Clinical Oncology	2002	119
BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome Zacharenia Saridaki, D. Papadatos-Pastos, Maria Tzardi, British Journal of Cancer	2010	118
Ribonucleotide reductase subunits M1 and M2 mRNA expression levels and clinical outcome of lung adenocarcinoma patients treated with docetaxel/gemcitabine John Souglakos, Ioannis Boukovinas, Miquel Tarón, British Journal of Cancer Tumor BiologyOncogenic AgentMedicineLung Adenocarcinoma PatientsQuantitative Real-time Pcr	2008	117
Peripheral blood circulating cytokeratin-19 mRNA-positive cells after the completion of adjuvant chemotherapy in patients with operable breast cancer Nikolaos Xenidis, Ioannis G. Vlachonikolis, D. Mavroudis, Annals of Oncology Tumor BiologyBreast OncologyMedicineImmunologyAdjuvant Chemotherapy	2003	103
Detection of cytokeratin-19 mRNA-positive cells in the peripheral blood and bone marrow of patients with operable breast cancer Anna Daskalaki, Sofia Agelaki, Maria Perraki, British Journal of Cancer	2009	99

Page 1